Drug Profile
Rovaleucel - Tessa Therapeutics
Alternative Names: Autologous EBV specific Cytotoxic T Lymphocytes - Tessa Therapeutics; EB-VST - Tessa Therapeutics; EBV-CTL; Epstein-Barr virus specific autologous cytotoxic T-lymphocytes therapy - Tessa Therapeutics; Epstein-Barr virus specific T cells - Tessa Therapeutics; TT 10; TT10-EB VSTLatest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator National Cancer Centre (Singapore)
- Developer National Cancer Centre (Singapore); Tessa Therapeutics
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Nasopharyngeal cancer
- No development reported Gastric cancer
Most Recent Events
- 07 Dec 2022 Rovaleucel is still in phase III trials for Nasopharyngeal cancer in USA, Thailand and Taiwan (NCT02578641)
- 28 Feb 2022 Tessa Therapeutics completes a phase III trial in Nasopharyngeal cancer (Combination therapy, Late-stage disease) in Malaysia, Singapore, Thailand, Taiwan and USA (IV) (NCT02578641)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Gastric-cancer in Singapore (IV, Infusion)